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Abstract
Point-of-care or point-of-use diagnostics are analytical devices that provide clinically relevant 
information without the need for a core clinical laboratory. In this review we define point-of-care 
diagnostics as portable versions of assays performed in a traditional clinical chemistry laboratory. 
This review discusses five areas relevant to human and animal health where increased attention 
could produce significant impact: veterinary medicine, space travel, sports medicine, emergency 
medicine, and operating room efficiency. For each of these areas, clinical need, available 
commercial products, and ongoing research into new devices are highlighted.
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1. Introduction
Point-of-care (POC) diagnostic tests provide clinically relevant information at the point-of-
use, without the need for sample processing or analysis from a remote clinical chemistry 
laboratory. The blood glucose meter, used for the management of diabetes, and the home 
pregnancy test (dipstick) are the most popular examples. However, recent advances in 
microfluidics combined with the decreasing cost and size of advanced electrochemical and 
optical sensors (Vashist et al., 2015) have broadened the range of applications for POC 
diagnostics. For example, these advances have made possible the burgeoning field of POC 
diagnostics for resource-limited settings, such as developing nations. Excellent reviews of 
POC diagnostic tests for global health have been published recently and thus are not 
included here (Chin et al., 2011, Yager et al., 2008). In addition to global health, other areas 
where portability and low cost are key drivers have benefitted from improvements in POC 
diagnostic technology. In this review, we focus on some of these niche areas that have not 
been covered extensively in the literature and which have a small market size compared to 
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health diagnostics in developed nations, or where the clinical benefit is still being actively 
investigated.
First, we briefly review the regulations governing POC diagnostics for human health, as they 
dictate how the diagnostics are used. Then we review POC diagnostics for veterinary 
medicine, space travel, sports medicine, emergency care, and operating room applications. A 
couple of these areas (e.g., veterinary medicine or emergency care) contain a vast number of 
potentially useful biomarkers that could be tested—enough to warrant a dedicated review 
article for each. Our goal here is not to exhaustively cover all possible applications within 
each area, but rather to increase the general awareness of the opportunities available and to 
focus on selected examples that have the greatest impact.
1.1 CLIA regulation
Healthcare-related diagnostic tests are an integral component of healthcare delivery in the 
US as they currently have a direct impact on up to 70% of healthcare-related decisions 
(www.lewin.com, 2005). This impact has been driven by the advances in science and 
technology of the 20th century. Prior to these advances, decision making was primarily based 
on patient history and physical examination (Burke, 2000). When these tests were first being 
used in diagnosis, most of these tests were performed at the side of the patient, and the 
individual practitioner had a significant amount of autonomy (Moore, 2005). However, the 
variability in quality of these tests ultimately led to regulation that mandated how these tests 
were to be performed (Berger, 1999a, b).
This regulation was primarily enforced by the Clinical Laboratory Improvement 
Amendment (CLIA) of 1988, which established regulatory standards for all human-related 
laboratories testing for diagnostic purposes (1988). This was, specifically, in response to an 
alarmingly high number of false negative results from in-house laboratories. Since its 
enactment, CLIA has required that all labs performing diagnostic tests of human samples 
must register with the Centers for Medicare and Medicaid Services (CMS). The process of 
registration is based on the type of testing that is to be performed, and a set of compliance 
standards are required for the given lab classification. This lab classification is determined 
by the complexity and clinical significance of the testing to be performed. The resulting 
CLIA requirements are more stringent for more complicated tests. As outlined in Table 1, 
diagnostic tests are scored by the FDA using seven independent criteria. These scores are 
then summed to determine the risk associated with the test. Diagnostic tests with scores of 
12 or less are in the moderate-complexity category. Scores higher than that are deemed high-
complexity (www.fda.gov, 2015a). CLIA defines waived-tests to be “simple laboratory 
examinations and procedures that have an insignificant risk of an erroneous result.” Sites 
that only perform waived tests must still have a CLIA certificate and follow the instructions 
from the manufacturer (Collopy et al., 2014, www.fda.gov, 2015b.)
These CLIA regulations led clinical practices to outsource many of their diagnostic tests to 
core laboratories - either regional centers like those operated by LabCorp or local centers 
within the hospital. This workflow is well-suited for tests where the results are not needed 
immediately, as the delivery of care would not be changed even if the information was 
immediate. However, there is a fairly recent push to perform certain tests at the POC 
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(Gubala et al., 2012, John and Price, 2013, McPartlin and O'Kennedy, 2014). Because POC 
tests are portable, they allow for an expedited workflow (Figure 1) and potentially shorter 
turnaround times. As a result, they carry the promise of providing the care giver with 
information at time points that can provide improved delivery of care and reduce the cost. 
However, to meet regulations, these tests must either be CLIA-waived or users of the devices 
must meet the associated standards in an attempt to prevent errors (Kost, 2001, 
Lewandrowski et al., 2011).
One example of a CLIA-waived, POC test is the blood glucose meter. With just a drop of 
blood from a finger-stick, these devices can inform the user of their current blood glucose 
levels and enable them to better self-regulate their blood glucose values. This self-regulation 
would not be possible if a blood glucose meter for use at the point-of-care did not exist. As 
the demand for home-health information continues to grow, additional devices are being 
developed for home use. The ability to create cost-effective, disposable test cartridges that 
can store reagents, direct the flow of solutions with passive microfluidics, and automatically 
read the generated signal leads to POC technologies becoming more user-friendly. In this 
review we describe POC tests that require CLIA regulation (i.e., those used in the emergency 
department and the operating room) as well as tests that do not, such as diagnostics for 
veterinary medicine.
2. Veterinary medicine
The common concerns between human health and animal health have made the development 
of veterinary diagnostics very appealing, especially for companion animals where the 
animals are brought to the controlled environment of a clinic. Transport and use of 
diagnostic tests on the farm increases the level of technical challenge and frequently 
decreases the price that the market will tolerate. The drivers pushing the development of 
more diagnostics, in addition to advances in human diagnostics, are the increasing 
willingness of owners of companion animals to spend money to keep their pets healthy, the 
increasing concern of customers about antibiotics and transmissible diseases in milk, eggs 
and meat, and widespread public concern over the spread of diseases through populations of 
wild and domestic animals.
2.1. Measurements of blood cells and blood chemistry
The first type of portable animal test to become widely available measures blood cell 
differentials. Originally, the automated cell counter developed by Becton-Dickenson for 
humans was adapted for animals; several versions of this differential counter are now 
commercially available as relatively small benchtop systems (ae.g. IDEXX LaserCyte Dx 
Hematology Analyzer (www.idexx.com, 2015a) and Abaxis Vetscan systems 
(www.abaxis.com, 2015a)). Abnormal white counts are used as indicators of infection; for 
example, specialized differential systems evaluate white blood cells in milk as an indicator 
of bovine mastitis.
Similarly, the automated analyzer for blood gases and electrolytes, first pioneered for 
humans by i-STAT, has been adapted for animals. Portable blood analyzers are frequently 
available in small clinics and even in portable veterinary facilities at strenuous equine 
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competitions where maintaining proper electrolyte balance can be challenging. A handheld 
analyzer for blood gases and electrolyte chemistry is sold by Abaxis (www.abaxis.com, 
2015b). The device weighs 0.64 kg, uses 95 μL of blood for the analysis, and performs the 
assay in 2 minutes. In addition to blood gases, a special cartridge is available to perform 
assays for cardiac troponin as an indicator of cardiac muscle damage.
2.2. Detection of specific infectious diseases
The adaptation of human diagnostics for specific infectious diseases in animals has been 
slower, but is well underway. The most frequently used POC tests target diseases of 
companion animals, especially where the animals are brought to local clinics.
The lateral flow test for heartworm is sold by several companies and widely used in small 
animal clinics. Other tests based on lateral flow immunoassays are commercially available 
for dogs and cats (e.g. Abaxis (www.abaxis.com, 2015c)) and include tests for canine 
parvovirus, Ehrlichia, Giardia, Anaplasma, Lyme disease, and feline leukemia/
immunodeficiency virus (Figure 2). The tests take 10-15 minutes to run and no reader is 
required.
More sophisticated biosensors for veterinary infectious diseases must address the 
requirements of device and reagent transport, operational simplicity, low cost, and data 
presentation in an actionable and useful format. The IDEXX SNAP tests (Figure 2) are 
based on sandwich immunoassays with added labels and washing to enhance signal 
discrimination compared to lateral flow tests (www.idexx.com, 2015b). The diagnostic 
system also includes a 0.66 kg reader that times the assay steps and transmits the data from 
up to six assays performed simultaneously on a single sample to central record-keeping files. 
Tests are available for the following pet diseases: heartworm, Ehrlichia, Anaplasma, Lyme 
disease, feline leukemia virus, feline immunodeficiency virus, Giardia, parvovirus, canine or 
feline pancreatitis, and feline heart disease. There is also a SNAP test for Leishmaniasis in 
dogs since dogs often supply the reservoir for disease transmission to humans, but this test is 
primarily used outside the US (O'Connor et al., 2013).
In addition to tests for dogs and cats, Abaxis sells an FDA-approved lateral flow test for 
Type A avian influenza that can be used to test chickens, ducks, turkeys, and geese 
(www.abaxis.com, 2015d). The test uses tracheal, oropharyngeal, or cloacal swabs to collect 
sample and insert it into the test cartridge. Yes/no answers are available in 15 minutes 
without a reader and only minimal technical training is required for operation. A SNAP test 
is also available for testing birds for Influenza A.
During the “bird flu” epidemic with repeated evidence of influenza transmission from birds 
to animals and people, quite a few of similar lateral flow assays for H5N1 influenza virus 
were tested in the field, but we could not find evidence that they have been commercially 
produced, possibly because of limited sensitivity or a cost too high to monitor wild bird 
populations. Nevertheless, some effort continues. Bai et al. (2012) reported using a portable 
surface plasmon resonance biosensor incorporating an aptamer (instead of an antibody) that 
recognized the H5N1 strain in poultry swab samples with a sensitivity ten times better than 
ELISA in 1.5 hours. The selectivity for the H5N1 compared to the six other influenza strains 
Cummins et al. Page 4
Biotechnol Adv. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was excellent. The cost and complexity of the device is still problematic, but the aptamer 
reagent might provide advantages for other, simpler POC tests.
The detection of Salmonella is of particular interest since it can be transmitted from bird 
feces, meat, or eggs to humans. While the experiments were performed in the lab, Gauglitz 
and colleagues demonstrated the use of a portable, low cost reflectometer to analyze sera 
from chickens infected with Salmonella (Ewald et al., 2015). They demonstrated that the 
antibodies from different chickens reacted differently against different strains of Salmonella 
and that C-reactive protein could be simultaneously measured as a generic indicator of the 
level of inflammation. The reactions required no labels or added reagents after the sample 
was passed over the chip, and the results were quantitative. Furthermore, the measurements 
of reactions to two different Salmonella strains and C-reactive protein were performed on a 
single chip. However, use of the chip and reader still required two syringe pumps and an 
eight-way valve, so there is still some engineering required to transfer this analytical system 
to a chicken shed. There are other diseases for which commercial flocks could benefit from 
point-of-use diagnostics not only because of rapid transmission and high mortality, but also 
because vaccines may be available. Such diseases include infectious bronchitis virus, 
infectious bursal disease, and Newcastle disease virus (O'Connor, Lawrence, 2013).
Milk is an attractive sample matrix for testing because of its easy accessibility as well as 
high value. Liebes et al. (2009) tested milk samples for antibodies to Brucella as an indicator 
of bovine pathogen exposure. They generated a chemiluminescent signal at the surface of an 
optical fiber coated with killed Brucella organisms. It was a multistep assay that would be 
difficult to perform in a barn, but the sensitivity was significantly better than a standard 
laboratory ELISA. While Brucellosis is of particular concern because it can be transmitted 
from wild populations of cloven-hooved animals to domestic cattle, most countries require 
that analyses be performed in a federally accredited laboratory.
Cattle and pigs are often quartered in groups, facilitating transmission of infectious diseases, 
especially those that are transmitted through aerosols and feces. Frequently, the causative 
agents are well distributed before an animal becomes symptomatic or there is a very short 
time between the onset of symptoms and death. Diseases of this type could be better 
controlled and animals saved if farmers or veterinarians were able diagnose the disease on 
site. Diseases that cause high mortality include bovine respiratory disease and porcine 
pseudorabies (O'Connor, Lawrence, 2013).
2.3. Testing to facilitate breeding
Several assays have been developed for detecting ovulation in cattle in order to facilitate 
artificial insemination. Monitoring progesterone levels in milk has proven to be more 
effective than monitoring oestrus not only in predicting ovulation, but also for detecting 
pregnancy and fertility problems (Velasco-Garcia and Mottram, 2003). Competitive 
immunoassays for progesterone in milk have been demonstrated using ELISA kits, 
amperometric biosensors, and optical biosensors, but as far as we can tell, a successful 
commercial product for use in the barn is not yet available.
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There is also a market for progesterone testing in horses to document the estrus cycle or to 
confirm pregnancy. This is particularly important for artificial insemination and embryo 
transfer procedures. However, it is not clear that a rapid analysis is of significantly more 
utility than shipment of plasma or serum to a central laboratory, but the opportunity to 
reduce the cost of a repetitively performed assay could be significant.
A more critical test for horses to be performed at the barn is the test for foal immunoglobulin 
(IgG). Foals that do not receive maternal immunoglobulins from milk immediately after 
birth are immunodeficient and highly susceptible to infection unless rapidly treated. IDEXX 
has developed a SNAP test for this condition (O'Connor, Lawrence, et al., 2013). Another 
common problem in foals is intoxication with botulinum toxin, and again this is a situation 
where waiting on transport of a serum sample to a central laboratory has a significant 
downside in consequent morbidity. On-site tests for botulinum toxin developed by the 
biodefense community could be adapted to address this need.
2.4. Drug residue analysis
Another area of veterinary application that has received a great deal of attention from 
researchers is the development of screening tests for drug residues in meat and milk 
(Sanvicens et al., 2011, Velasco-Garcia and Mottram, 2003). Research labs and companies 
have been developing tests for antibiotics in milk that can be used in the barn or at the dairy 
processing facility for over 30 years, and excellent reviews are available (Davis and Higson, 
2010; Samsonova et al., 2012; Babington et al., 2012; Danaher and Jordan, 2013). Key 
issues for continued improvement include elimination of any sample preparation, minimized 
use of complex equipment, and multiplexed analysis to detect multiple antibiotics 
simultaneously.
Surface plasmon resonance (SPR) has been used successfully to detect sulfonamides in milk 
and pig bile at levels below that of standard laboratory methods. The same instrument has 
also been used to detect illegal growth promoting drugs in calf urine. SPR is attractive 
because the assays are label-free and multiple tests can be run simultaneously; detection of 
three different families of antibiotics were measured below regulatory levels. Imaging SPR 
can detect an even wider array of antibiotic residues in milk using antibody microarrays for 
immunodetection at levels consistent with regulatory guidelines. However, simpler systems 
are needed for use in the barn or stockyard.
The portable array biosensor commercialized by mBio Diagnostics (www.mbiodx.com) has 
been used for simultaneous and quantitative immunoassay of three antibiotics in milk 
(McGrath et al., 2015). No sample preparation was required, and sensitivities ranged from 
0.13 to 2 ng/mL, meeting the European legislated requirements. The device is based on 
evanescent illumination of a disposable cartridge including fluorescent reagents and planar 
waveguide modified with capture antibody spots. It simple to use, with sample in-answer out 
capability, and inexpensive.
Screen-printed amperometric sensors are not quite as sensitive for detecting antibiotics in 
milk, but much simpler to use. Screen-printed carbon electrodes, similar to those in over-the-
counter glucose tests, were used to detect the banned antibiotic clembuterol in bovine hair 
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(Regiart et al., 2013). The assay was a competitive immunoassay that produced an 
electroactive product and produced excellent sensitivity (0.008 ng/mL), but the sample 
preparation required two hours and involved multiple steps and hazardous chemicals.
2.5. Future directions
The biggest challenge in getting portable diagnostic tests into the veterinary market is not 
convincing veterinarians to use them. Once a test is proven to provide a reliable basis on 
which a veterinarian can make a clinical decision, the hurdles of cost, ease of use, and 
storage stability are still critical. The cost of the technologies included in portable tests is 
going down fast. Tests that use glucose meters (Gu et al., 2015) or cell phones (Yu et al., 
2015; Ludwig et al., 2015) to analyze milk samples are in the research phase. Fabrication 
technologies, including cloned reagents, especially synthetic antibodies, ink jet printing of 
biologics and optoelectronic circuits, organic optics, and roll-to-roll fabrication and 
assembly of devices will bring the cost down and enable the production of more robust and 
disposable tests.
Inexpensive methods for measuring DNA or RNA will also fill a major void for veterinary 
applications, particularly for diagnosis of viral and mycoplasma infections (Dahlhausen, 
2010). Neogen Corporation has a range of diagnostic products for food and animal safety 
based on a 4-plate processing system for detection of pathogens, with results in less than 2 
hours. However, it is still a laboratory system requiring a sophisticated user. In addition to 
genetic characterization for a wide variety of breeding animals where a timely response is 
less often crucial, mail in samples can currently be tested for bovine diarrhea virus, porcine 
epidemic diarrhea virus, porcine stress syndrome, porcine reproductive and respiratory 
syndrome virus, or porcine circovirus type 2 (e.g., (www.neogen.com, 2015)). Other 
companies, such as Biomerieux sell kits and benchtop devices for tests based on genetic 
identification of diseases, but they are all intended for use in a laboratory, not in a barn 
(www.biomerieux-industry.com, 2015). Isothermal amplification approaches may eventually 
go a long way toward moving tests for pathogens based on oligonucleotide binding out of 
the lab. The research community has extensive efforts to move oligonucleotide amplification 
tests onto automated chips, but making the entire analytical system simple and robust 
remains challenging.
While there are tests for diseases that cause diarrhea or respiratory distress in horses and 
food animals, nearly all of these tests require shipping a sample to a central laboratory. The 
time for shipping as well as analysis is a serious problem for animals with life threatening 
illnesses; usually the veterinarian must start treatment days before the pathogen is identified 
and initial treatment costs of $5000 for a large animal are not unusual. If the disease is 
highly infectious, the delay in getting results has ramifications that impact groups of animals 
and even wide geographic regions if quarantines are not established in time. The market 
exists, and the opportunity for innovative technologies to find a niche is wide open.
3. Space travel
The amount of time astronauts spend in space has steadily increased in recent decades, first 
with the establishment of the Mir space station, and more recently with the International 
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Space Station. Unlike earlier low Earth orbit space flights, which were of short duration with 
potential for a quick return to Earth in the event of a medical emergency, future missions 
will be much longer in duration: return mission to the moon (14 days), a stay at a moon base 
(180 days), and human exploration to Mars (395 days). Long missions pose significant 
challenges to the use of diagnostics for monitoring astronaut health. For example, a mission 
to Mars prevents the transport of samples to Earth for analysis and also makes impossible 
shipments of new consumables such as reagents or supplies. As mission lengths continue to 
increase, the need for diagnostics that detect a wide variety of medical conditions and 
measure multiple physiological parameters, but are compatible with the rigors of space 
travel, will continue to grow.
3.1. Human health requirements
The space environment possesses unique health hazards and challenges that are not found on 
Earth. The key risks for an astronaut are: bone loss, radiation exposure, cardiovascular de-
conditioning, muscle loss, and vestibular re-conditioning (Buckey 1999). These conditions 
begin to develop within days of first entering orbit and progress as the spaceflight duration 
grows. Some of the effects, such as cardiovascular de-conditioning and muscle loss, can be 
mitigated through exercise. Research on animals suggests that artificial gravity (e.g., through 
the use of an on-board short-arm centrifuge) protects agains bone mineral loss and could be 
beneficial for humans as well (Davis 1999). However, the threat of radiation exposure is 
considered to be the primary hazard associated with spaceflight (Nicogossian et al., 1994). 
Completely shielding astronauts from radiation while inside a space vehicle would require 
prohibitively large masses, so a balance must be struck between acceptably low radiation 
exposure and vehicle mass (Nachtwey 1991). This same tradeoff between safety and mass 
must be considered for spacesuits when astronauts are outside a vehicle or shelter (e.g., on 
the surface of Mars).
In addition to the physiological changes and health hazards caused by the space 
environment, astronauts are also susceptible to human disease and injury. It is impractical to 
transport samples to Earth for diagnosis, and in the case of a trip to Mars it will be 
impossible. Astronauts must have access to the instruments necessary to diagnose and treat a 
wide range of diseases and injuries. NASA maintains an evolving list of medical conditions 
that could occur during long-duration space travel in the Exploration Medical Condition List 
(EMCL) (humanresearchwiki.jsc.nasa.gov, 2015a). There are 88 conditions listed and they 
range from life-threatening conditions, such as sudden cardiac arrest, to fairly minor 
conditions such as a skin abrasion. Of these 88 conditions, 25 require fluid specimens for 
diagnosis, making them ideal candidates for POC analysis. Table 2 summarizes the 
conditions.
All of the conditions listed in Table 2 can be diagnosed by quantifying cells, electrolytes, 
ions, crystals (for urinalysis), small molecules, or large biomolecules (e.g., proteins) within a 
fluid specimen. Fluid specimens relevant to human health are saliva, urine, blood, and 
potable water (to monitor contamination). For example, excessive radiation exposure can be 
diagnosed by checking for a decrease in peripheral blood lymphocytes and by measuring the 
expression of cytogenetic markers such as DNA repair gene GADD45 (Blakely et al., 2003; 
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Semkova et al., 1995). Cardiac arrest can be diagnosed by quantifying the levels of a 
biomolecule, C-reactive protein, in the blood. The instruments for counting cells and 
measuring the levels of biomarkers are commonly found in core clinical laboratories on 
Earth. Protein tests, including C-reactive protein, have been reported using lateral flow 
assays (which may be compatible with use in space) and other biosensors which have not 
been optimized for zero gravity. Thus, while the base technologies for use on Earth may 
exist, adapting them for both storage and use in space will be a significant engineering 
challenge.
3.2. Diagnostic requirements
Space travel poses unique design challenges to portable POC diagnostics. The POC 
diagnostic must survive transportation to space, where it is exposed to many times the 
normal gravitational force during launch and severe vibration. Once in orbit, the diagnostic 
will be in an environment characterized by low humidity, low gravity, elevated radiation 
levels compared to Earth, and an absence of refrigeration.
Researchers at NASA have developed a list of design principles for the development of 
microfluidic biomedical diagnostics in space: minimized resource consumption, modularity, 
long shelf life, and gravitational independence (Nelson 2011). While some of these 
principles align with recent trends in the development of POC devices for resource-limited 
settings (e.g., long shelf life), others are unique to space travel.
One of the main design challenges for space-based POC diagnostics is minimizing resource 
consumption. Resource consumption has two components: the resources consumed to 
perform the diagnostic and the diagnostic device itself. Most POC diagnostics are disposable 
because a disposable device limits the chances of cross-contamination and reduces cost 
During space travel, mass and volume-the “load” associated with a diagnostic-is a key 
consideration before deployment and must always be minimized. Therefore, the use of 
disposable pipettes or lancets, and even disposable microfluidic chips, is not optimal. 
Instead, reversing a trend that is common in the lab-on-a-chip field, diagnostics for space 
travel should be reusable instead of disposable (Nelson 2011). Minimizing resource 
consumption also reduces the amount of biohazardous waste generated.
Reusable POC diagnostic devices for space will need to be adaptable to accommodate a 
wide range of human samples and diagnostic tests. Reusable modules would also save space 
and minimize the load associated with the diagnostic device. For example, a complete blood 
count might need to be performed on a sample simultaneously with an analysis of proteins in 
the serum. This analysis could be accomplished by linking together different recognition 
modules in series that perform each of the diagnostics (Nelson 2011). On Earth the solution 
is to have dedicated diagnostics for each type of test. This approach will be impossible in 
space, so a modular approach provides a more attractive alternative. A modular device that 
can be disassembled is also easier to clean, which is another design consideration for 
reusable diagnostic devices suitable for space travel.
The reagents required for the POC diagnostics should have a long shelf life, of up to a few 
years in the case of a Mars mission without refrigeration(Crucian et al., 2013). Strategies 
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exist to extend the shelf life of antibodies, but alternative recognition elements that are not as 
susceptible to degradation may extend the shelf life even further.
Lastly, diagnostic devices must be able to function normally in the absence of gravity. This 
problem is not encountered on Earth and will require the development of novel methods for 
manipulating fluids within the diagnostic device. For example, while some analytical 
methods that work on Earth, such as capillary electrophoresis, have been demonstrated in 
low gravity environments (Culbertson et al., 2005), other methods, such as gravity-driven 
fluid flow, are impractical. Passive pumping methods that rely on surface tension or surface 
wetting provide attractive solutions for manipulating fluids because they are insensitive to 
gravity, contain no moving parts, require no external energy sources, and add minimal 
weight to the diagnostic device.
Bubbles are another example of an Earth-based problem that will need to be re-examined in 
the context of microgravity. Bubbles are removed from devices via a bubble trap on Earth. 
However, these traps rely on gravity and will not work in space. New methods for removing 
or trapping bubbles can only be developed by studying the behavior of microfluidic devices 
in low gravity environments.
3.3. Devices deployed on the International Space Station
Only two POC devices have been deployed on the International Space Station (ISS): the i-
STAT and the Reflotron (humanresearchwiki.jsc.nasa.gov, 2015b). Both of these diagnostics 
measure blood chemistry.
The i-STAT is a portable blood chemistry analyzer (Figure 2). It was developed by Abbot 
Labs in the early 1990s (Erickson and Wilding, 1993) and was the first microfluidic POC 
device to market. The device has found use in hospitals (Papadea et al., 2002), but because 
of its small size and low power requirements, it is also well-suited for use in space. The i-
STAT was used to measure the blood chemistry of 21 astronauts during five space shuttle 
missions in the mid-1990s (Smith et al., 1997). In this study, a chip that can measure six 
analytes was used to measure sodium, potassium, glucose, ionized calcium, pH, and 
hematocrit. A variety of chips are available for the i-STAT. Analytes are quantified with 
electrochemical sensors: potentiometry for electrolytes and pH, amperometry for glucose, 
and conductance for hematocrit measurements. While the i-STAT can provide a reading for 
hematocrict, it cannot provide detailed blood cell sub-populations. A finger prick is used to 
collect 85 μL of blood which is then deposited on a cartridge. Analysis takes 120 seconds. 
The cartridge is inserted into the handheld reader where an on-chip vacuum is used to propel 
the sample through the chip. Analyses performed on the shuttle agreed well with Earth-
based analysis, except for hematocrit. However, others have documented inaccurate 
hematocrit results in Earth-based clinical use (Erickson and Wilding, 1993, Papadea, Foster, 
2002), suggesting these errors are intrinsic to the i-STAT and not a result of microgravity. 
The i-STAT currently resides on the ISS but is not frequently used because of the 6-month 
shelf-life of the cartridges (ntrs.nasa.gov, 2015).
The Reflotron IV biochemical analyzer by Boehringer Mannheim has also been tested in 
space on seventeen cosmonauts over six missions to the Mir station (Markin et al., 1998). 
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The Reflotron IV was used to measure the activity of glutamate-oxalo-acetate transaminase 
(GOT), glutamate pyruvate transaminase (GPT), creatine kinase (CK), gamma-
glutamyltransferase (gamma-GT), and total and pancreatic amylase. The concentration of 
several analytes was measured as well: hemoglobin, glucose, total bilirubin, uric acid, urea, 
creatinine, total, high density lipoproteins (HDL-) and low density lipoproteins (LDL-) 
cholesterol, and triglycerides. The Reflotron is a table-top instrument and is not as portable 
as the i-STAT. It uses paper strips and dry chemistry to perform the analysis. An optical 
readout measures the reflectance of the color after the chemical reaction (Markin, 
Strogonova, 1998).
While the i-STAT and Reflotron IV have been deployed to the ISS, a recent NASA report 
highlighted that no one diagnostic device has the capability to perform a full blood analysis 
(ntrs.nasa.gov, 2015.). To address these unmet needs, other devices are currently being 
developed and validated in space or in low-gravity environments for eventual use on long-
duration space missions. We highlight some of these efforts below.
3.4. Ongoing research
One effort focused on developing a microfabricated flow cytometer is the Hemocue, which 
performs differential blood cell counts (Crucian et al., 2013). Although the device was not 
originally designed for use in space, its small footprint, low power requirements, and ease of 
use make it attractive for cytometry in space. A 10 μL sample of blood from a finger prick is 
passively aspirated into a cartridge which contains lysing reagent and a nuclear stain. The 
cartridge is inserted into the device where it is imaged via a CCD and the blood cell counts 
are determined from cell morphology and staining. The total analysis time is 3 minutes 20 
seconds. Hemocue was validated in parabolic flight (temporary microgravity) and was found 
to be suitable for use in space. The Hemocue produced results consistent with a reference 
cytometer on the ground. Blood sample aspiration is not affected by low gravity nor is the 
assay.
Another device that has been tested in parabolic flight and aboard the ISS is the fiber optic-
based flow cytometer Microflow1 (Cohen et al., 2008, Dubeau-Laramée et al., 2014). Cells 
flow in a capillary tube perpendicular to a 488 nm laser diode excitation source. Reflected 
and scattered light is captured by optical fibers sitting perpendicular to both the capillary and 
excitation light. The system can detect the fluorescent stain phycoerythrin-Cy5 and side 
scatter. The system can enumerate leukocyte sub-populations via immunophenotyping and 
can also quantify cytokine levels using fluorescent bead-based assays (IL-2, IL-4, TNFalpha, 
IFNgamma). The system compared favorably to ground-based FACS array cytometer (BD 
Biosciences). While initial cytometry results are encouraging, samples were prepared on the 
ground before launch or before parabolic flight. The device produced cell counts comparable 
to the ground-based FACS. It was able to successfully discriminate granulocytes, monocytes, 
CD4+ lymphocytes, and CD4‒ lymphocytes in a 40 μL blood sample. The system does not 
need sheathing fluid because the excitation laser illuminates the width of the capillary, which 
helps reduce the amount of reagent needed and the amount of biohazardous waste generated. 
Optical alignment, a potential drawback for using these devices in a high vibration 
environment such as space flight, is also eliminated because of the illumination strategy. It 
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takes 50 seconds for the device to analyze the sample. Results indicated that Microflow1 
performance did not degrade in a microgravity environment.
A group from CalTech has tested a microfabricated flow cytometer in microgravity during 
parabolic flight (Shi et al., 2009). The authors demonstrated leukocyte count and two-part 
differential (lymphocyte vs non-lymphocyte) counts from a blood sample. DNA and RNA in 
the leukocytes are stained with acridine orange. The fluorescence intensity is used to 
differentiate lymphocytes from non-lymphocytes. Non-lymphocytes typically contain high 
levels of RNA, which shows up as a brighter fluorescence intensity in the device (Steinkamp 
et al., 1973). Small dimension channels within the device physically constrain the cells and 
eliminate the need for sheath flow. Total sample volume was 50 μL or less. Results are 
comparable to a commercial hemocytometer. The researchers demonstrated that 
microgravity from parabolic flight does not negatively affect the counts. There are a few 
drawbacks to the device. Samples were collected and loaded before testing in microgravity. 
Also, samples required processing before into the device loading: blood was diluted 10× 
before injection. The unit is self-contained but requires a laptop for readout. A mini 
peristaltic pump is used to move the blood sample.
Another recent research effort recognizes the need to combine both molecular analysis and 
cellular analysis into a single device (Straume et al., 2013). As part of a NASA/Sandia joint 
effort, the authors aim to create a portable device that can perform these analyses and also 
analyze molecules present in breath.
Another application area for POC testing is monitoring microorganisms (bacteria and fungi) 
within spacecraft. Microorganisms in spacecraft have been monitored for years by NASA 
and in Russia (Maule et al., 2009). Bacteria growing on surfaces within the ISS have been 
characterized, with the most common strains in air and on surfaces being Staphylococcus 
and Bacillus spp (Van Houdt et al., 2012). Bacteria and fungi are currently monitored by 
pressing agar “contact slides” onto a surface and observing culture growth over five days 
(Maule et al., 2009). This potential health hazard, not covered by the Exploration Medical 
Condition List, is another health-related application that requires POC testing. As a result, 
one group has begun testing on a new device, the Lab-on-a-chip Application Development 
Portable Test System (LOCAD-PTS) (Maule et al., 2009, Morris et al., 2012). This device is 
used to monitor bacterial colonies that grow on surfaces within the habitat. The assay detects 
lipopolysaccharides (endotoxins) present in the cell wall of gram-negative bacteria using a 
limulus amebocyte lysate (LAL) assay (Maule et al., 2009). Testing takes 15 minutes, 
compared to the previous standard which took five days. A more recent version of the device 
also detects beta-glucan, a component of fungi cell walls, and lipoteichoic acid (LTA), a 
component of gram-positive bacterial cell walls. The devices have been tested in the ISS and 
detected a greater occurrence of potentially dangerous (i.e., endotoxin producing) bacteria 
than was previously documented. The device is a handheld spectrophotometer with a built-in 
pump that moves the liquid via vacuum. Samples are deposited on a cartridge which is then 
inserted into the reader. Endotoxin units (EU) are displayed on the device readout. A custom 
sample collector that serves as a swab and pipette was used to collect sample and then 
deposit them, suspended in 25 μL of water, onto the cartridge. The device contains a built-in 
control.
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3.5. Future directions
Even now, the iStat represents the state-of-the-art technology for POC diagnostics in space. 
However, promising advances are being made in portable diagnostics that can provide a 
range of analytical capabilities for long-term space travel. While the detection of key 
analytes has been demonstrated, additional assays that can detect a larger number of analytes 
still need to be adapted for use in space. Likewise, cell counts have been demonstrated in 
microfabricated flow cytometers, but a larger number of cell types must be included to give 
the devices the necessary medical value for long-term space travel.
Despite impressive recent technological advances, much work remains before a reusable and 
versatile POC diagnostic suitable for long-term space travel is deployed. Not only must new 
technologies be developed, but a greater understanding of the effects of microgravity on 
biological and physical systems is needed. In particular, our understanding of the effects of 
long-term microgravity on the human body and the appropriate biomarkers to quantify those 
effects remains incomplete. The behavior of fluids in microgravity environments and the 
development of devices that can effectively manipulate fluids in such environments also 
requires further study. Continued research and development during short and long duration 
space flights will address these deficiencies.
4. Sports medicine
To date, POC diagnostics have found limited application in sports medicine. However, POC 
applications in sports seem likely in the future because of the need for clinical diagnoses in a 
portable format and in potentially remote locations. The most likely candidates for POC 
diagnostics are monitoring athletes for doping and for diagnosing injury.
4.1. Doping
The death of an Olympic cyclist in 1960 motivated athletic authorities to establish rules for 
doping in cycling, and since the 1960's efforts to monitor doping have continued to evolve 
(Catlin et al., 2008). In 1999 the International Olympic Committee established the World 
Anti-Doping Agency (WADA) which published standardized definitions of doping and 
established testing procedures in 2004 with the World Anti-Doping Code (Mazzei et al., 
2014, www.wada-ama.org, 2015). WADA offers a comprehensive definition of doping: the 
attempt of an athlete to improve performance by using a substance or method. WADA may 
include a substance on the “prohibited list” if it meets any two of three criteria: (1) the 
substance or method has the potential to enhance sport performance, (2) the use of the 
substance or method represents an actual or potential health risk to the athlete, and (3) 
WADA determines the use of a substance or method is against the spirit of the sport 
(www.wada-ama.org, 2015). The broad definition of doping causes a wide variety of 
substances to be prohibited, ranging from common doping agents like steroids to less 
obvious substances like insulin. In addition to small molecules, increasing blood cell counts 
is considered doping. The wide range of abused substances or methods means that no one 
POC detection method is ideal.
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Many analytical techniques can be used to test for doping: gas chromatography, 
immunoassay, gas chromatography-mass spectrometry (GC-MS), liquid chromatography-
mass spectrometry (LC-MS), isotope ratio mass spectrometry (IRMS) (Catlin et al., 2008). 
GC-MS and LC-MS are the de facto standards; however, miniaturized GC-MS and LC-MS 
systems remain at the research stage and currently available clinical instruments are 
unsuitable for point-of-care analysis. Immunoassays have a role to play in doping control, 
but their main drawback is that they lack the selectivity to distinguish between endogenous 
steroids and exogenous steroids with similar structure. To date, they are not widely used to 
test for doping in athletes, but they may have a role for selecting athletes at the point-of-use 
who should undergo further testing. For a thorough review of affinity-based biosensors used 
to detect doping agents, see (Mazzei et al., 2014). In addition to testing for molecules in an 
athlete's blood, flow cytometry can be used to test for increased numbers of red blood cells. 
Point-of-care devices for counting blood cells have been developed, but they have yet to be 
applied to doping control. One unexplored POC technique for testing doping is capillary 
electrophoresis (Harrison, 2013). CE is more portable than the gold standard methods now 
used, and it can be adapted to detect small molecules such as hormones to large biologicals, 
like proteins. It could also be adapted to check cell counts.
4.2. Physiological monitoring
The monitoring of athlete health and consequent adaptations in training intensity could 
benefit from the development of POC analytical devices. Sweat is a readily accessible 
sample matrix that contains a wealth of potentially useful biomarkers, as well as providing a 
readout of hydration. Hyponatremia, a sodium concentration < 135 mEq/L, can result from 
drinking excessive water during endurance sports and is potentially fatal. Marathon runners 
are particularly susceptible--in the 2002 Boston Marathon, 13% of runners suffered from 
hyponatremia (Almond et al., 2005).
While one could measure sodium levels in sweat directly, e.g., with ISFETS (Bezegh et al., 
1988), it is easier to measure pH, which is a surrogate for sodium levels. Portable sensors for 
measuring sweat pH have been developed, as shown in Figure 2 (Curto et al., 2012). In this 
sensor, researchers created a wearable “barcode” that indicated pH via the colors of the bars. 
An absorbent pad was used to wick sweat from the skin and transport it to the barcode. 
Wearable textile sensors have also been developed to measure physiological conditions from 
sweat (Coyle et al., 2009). In these textiles, pH sensitive dye was immobilized into a small 
patch of fabric and optical sensors were mounted near the patch. Another sensor uses a 
smartphone to measure the change in color of a commercially available pH paper once sweat 
is placed on it (Oncescu et al., 2013).
Blood lactate is another potentially useful metabolite to monitor during training. The level of 
lactate can tell an athlete if he or she is training in the correct/optimal zone and at the 
appropriate intensity. The i-STAT can be used to measure blood lactate but there are other 
analyzers specific to blood lactate that are less expensive (e.g., Accusport). The i-STAT and 
Accusport lactate analyzers produced similar results for blood lactate for samples taken at 
rest, during moderate exercise, and during maximal exercise (Dascombe et al., 2007). 
However, others have found that the portable analyzers, and the Accusport in particular, do 
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not agree with laboratory-based lactate analyzers (Buckley et al., 2003). Erroneous lactate 
measurements can be problematic because their readings are used to establish the intensity 
of workouts.
Other useful serum biomarkers for monitoring workout intensity are creatine kinase (CK) 
and lactate dehydrogenase (LDH) (Brancaccio et al., 2008). Increased CK levels are a sign 
that muscles have been exercised outside of normal metabolic range (i.e., exercise intensity 
exceeds muscle capacity), but very high levels of CK can also be indicative of muscle injury 
(Mougios, 2007). Therefore, CK monitoring may be useful for monitoring the intensity of 
training sessions (Brancaccio, Maffulli, 2008). Serum levels of LDH increase after exercise, 
too. The level of increase depends on exercise intensity and the fitness level of the 
individual. CK levels can be used to monitor muscle recovery after strenuous exercise and 
LDH levels can be used to gauge muscle response after training (Brancaccio et al., 2008). A 
miniaturized capillary electrophoresis device that measures LDH activity has been 
developed (Zhuang et al., 2007), but not for use as a POC diagnostic. Creatine kinase assays 
have been developed because the CK isoform CK-MB is a potentially useful biomarker for 
detecting myocardial infarction (Brancaccio et al., 2008).
4.3. Traumatic brain injury
It is estimated that approximately 300,000 sports-related concussions occur in the United 
States annually (Thurman et al., 1998). The definition and assessment of a sports concussion 
is defined by the Zurich Consensus statement, which was designed to be used by physicians 
and sports trainers (McCrory et al., 2009). A preliminary evidence-based diagnosis is 
performed at the point-of-care using a Sports Concussion Assessment Tool (SCAT2) card, 
which contains a checklist and questionnaire for use by medical professionals. Further 
analyses, away from the point-of-care, are also subjective: neuroimaging and psychological 
evaluation. Biomarkers offer an objective measure and many have been studied possible 
links to concussions or mild-to-moderate traumatic brain injury: S100B, neuron-specific 
enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase 
L1 (UCHL1), and myelin basic protein (MBP) (Jeter et al., 2013). Other candidate markers 
have been suggested (Shan et al., 2015). However, the efficacy of these markers in 
diagnosing concussion remains unknown, and it is unlikely that any single biomarker is 
sufficient to diagnose traumatic brain injury (North et al., 2012). For example, some 
biomarkers (e.g., S100B) do not easily cross the blood brain barrier, leading to inconsistent 
levels of protein in serum and cerebrospinal fluid.
Multiple lateral flow immunoassays have been demonstrated for detecting biomarkers 
(North et al., 2012). These immunoassays can detect common biomarkers such as the 
protein S100B, glial fibrillary acidic protein (GFAP), and neuron-specific enolase (NSE). 
They use sera as the sample input. More recently, microfluidic devices have begun to show 
promise as POC assays for biomarkers of traumatic brain injury. For example, Apori et al. 
(2011) demonstrated a capillary electrophoresis device for the detection of S100B and C-
reactive protein in human cerebral spinal fluid.
The challenges for detecting biomarkers are twofold. The first major challenge is 
establishing that biomarkers can accurately represent traumatic brain injury. So far, 
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definitive evidence is lacking. Second, questions remain about which sample has greater 
diagnostic value: cerebral spinal fluid or serum. Serum is more accessible, but the biomarker 
levels tend to be lower (as much as 10×). On the other hand, cerebral spinal fluid can hardly 
be collected in a locker room. At any rate, the infrastructure exists to create an assay for 
traumatic brain injury biomarkers, but the clinical evidence must catch up.
4.4. Future directions
The diagnostic needs most relevant to sports medicine lend themselves to a portable format. 
Detection of doping has historically been performed using clinical laboratory equipment, 
such as mass spectrometry. As advances in microfabricated mass spectrometry systems 
continue, these systems will move out of core lab facilities and evolve into portable POC 
devices that can be used at a sporting event. Another challenge will be the creation of 
adaptable diagnostic devices that can evolve as doping strategies change. In the case of 
antibody-based assays, this means developing new and specific antibodies for doping agents 
that may change frequently or that recognize a related biomarker within the body. In the case 
of MS systems, it means looking for new chemical signatures in a sample.
Significant research into POC assays for traumatic brain injury has been driven mainly by 
military research funding because of the critical need to assess concussive injury in military 
personnel. Most POC methods have been focused on developing rapid and sensitive assays 
for specific biomarkers in serum or cerebrospinal fluid. However, there is still debate about 
which biomarkers, or groups of biomarkers, contain the highest diagnostic value. Continued 
research will shed new light on the role that each play in diagnosing traumatic brain injury. 
Furthermore, it is likely that assessment of traumatic brain injury at the point-of-care will 
include a psychological assessment in addition to the quantification of biomarkers.
Lastly, challenges remain in POC physiological monitoring for sports applications. 
Diagnostic tests are used to monitor athlete training, and in particular gauging muscle injury 
as a result of over-training. However, as with traumatic brain injury, there is debate about the 
most appropriate biomarkers. Further research is needed to identify the effects of exercise on 
the body, and in particular the role it plays in changing biomarker levels.
5. Emergency department
The role of the emergency department (ED) in the delivery of healthcare has evolved over 
the years. Whereas the ED was originally responsible for emergency cases alone, today, the 
ED is the location where a large number of Americans (28%) receive their primary 
healthcare. In 2010, emergency departments in the US managed 130 million encounters 
(Pitts et al., 2010). Unfortunately, the emergency medicine setting is one of the clinical 
settings with the highest cost, and this cost is rising. Between 2003 and 2011, the average 
cost of a visit to the ED rose from $560 to over $1300 (a 240% increase) (Schuur et al., 
2014). As a result of the increased rate of usage, the ED is becoming overcrowded (Kanzaria 
et al., 2015). This crowding leads to the ED being stressed beyond its current capabilities, 
making it necessary to triage patients to best use available resources. Even so, there are 
increased waiting times, a lack of beds, and an increased frequency of patients leaving the 
ED without treatment.
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There are many efforts underway to improve the care and lower the cost in the ED. One of 
these is to expedite the diagnostic process with cost-effective, POC tests (Fermann and 
Suyama, 2002). For diseases where the turnaround time is the limiting factor, the 
implementation of such POC testing has been shown to improve healthcare delivery 
(Rooney and Schilling, 2014). Here we focus on POC testing that is used to diagnose 
adverse cardiac events in the emergency department. Other analytes that are commonly 
measured in the ER include glucose, urine, pregnancy hormones, chemistry panels, 
antibodies against HIV, hemoglobin, D-dimer, lipids, coagulation markers, and drugs of 
abuse.
Cardiovascular disease is the leading cause of death in the US. There are many reviews 
about cardiac biomarkers and the biosensors used for their detection (Ahmad et al., 2012, 
Braunwald, 2008, Collinson et al., 2015, Qureshi et al., 2012). Biomarkers that have been 
used include troponin, BNP, CK-MB, myoglobin, D-dimer, and C-reactive protein. The 
biomarkers have shown differences in the cutoff values that should be used for diagnosis 
between men and women (Daniels and Maisel, 2015). Additional protein biomarkers, such 
as sCD40 and copeptin, have recently been identified that provide opportunities for future 
high-impact diagnostic tests (Jaffe et al., 2006, Maisel and Choudhary, 2012). Additional 
studies identify micro-RNAs as ideal biomarkers for diagnostics (D'Alessandra et al., 2010, 
Ji et al., 2009). Here we briefly describe POC tests used in the emergency room to diagnose 
myocardial infarction (troponin, CK-MB, and myoglobin) and acute heart failure (BNP) as 
examples of biosensors useful in the ED niche.
5.1. Myocardial infarction: (troponin, CK-MB, myoglobin)
Chest pain is a common symptom of people who attend the ED (∼5%) (Fothergill et al., 
1993). This is a common symptom associated with acute myocardial infarctions (AMI), but 
the majority of patients who present with chest pain do not have AMI. Because it is essential 
to deliver treatment to patients with a recent AMI, it is essential to quickly diagnose those 
who present with chest pain (Reichlin et al., 2012). An electrocardiogram can identify ST-
segment elevation myocardial infarction (STEMI), but there are cases of acute myocardial 
infarction without elevated ST-segment (NSTEMI). In these cases, diagnosis is made based 
on measuring the cardiac biomarkers associated with myocardial necrosis – most notably 
troponin (Sabatine et al., 2002, Thygesen et al., 2010).
There are three tissue-specific troponin isoforms (I, T, and C). Troponin C is not used in the 
diagnosis of cardiac injury because it is shared by slow-twitch skeletal muscles. However, 
cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are used in such diagnostic tests. 
These concentrations rise 4–6 hours after the onset of symptoms, and they peak at 18–24 
hours (Babuin and Jaffe, 2005). Antibodies have been generated with specificity for the cTnI 
and cTnT isoforms and incorporated into assays for those targets. Elevated levels of cTnI 
and cTnT indicate cardiac injury, and the American College of Cardiology has included 
elevated levels of cardiac troponin (I or T) in the criteria for AMI (Antman et al., 2000). The 
time-dependent concentration profiles are similar for the two isoforms, providing similar 
clinical information about AMI. The cut-off point for troponin levels that suggest AMI has 
been defined as the 99th percentile of a reference control group (3 standard deviations above 
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the mean). However, new assays have been developed with improved or “high” sensitivity, 
and there is new work being done to identify the actual concentrations that are associated 
with AMI (Apple and Collinson, 2012, Giannitsis et al., 2010, Keller et al., 2009, Mahajan 
and Jarolim, 2011, Reichlin et al., 2009, Saunders et al., 2011).
Prior to the use of troponin as a biomarker, creatine kinase (CK) and the MB fraction of 
creatine kinase (CK-MB) were used to diagnose an AMI (Saenger and Jaffe, 2008; 
Christenson and Azzazy, 1998). However, because of the abundance of CK-MB in skeletal 
muscle, the assay specificity is limited and has been replaced by assays for troponin 
(Panteghini, 1998). However, tests for CK-MB are still very useful for diagnosis of re-
infarction and are included in many multiplexed diagnostic panels. The CK-MB also uses 
the 99th percentile cut-off criterion. While myoglobin has been disproven as a definitive 
biomarker for AMI diagnosis, the myoglobin level in the bloodstream rises much faster than 
CK-MB or troponin do, and myoglobin assays are still useful in screening (Apple et al., 
1999, Kim et al., 2014b).
To expedite diagnosis, many EDs have successfully introduced POC devices to test for cTnI 
(Bingisser et al., 2012, Friess and Stark, 2009). However, while there are many different 
devices currently on the market that are capable of making this measurement (Yang and Min 
Zhou, 2006), there are currently no CLIA-waived tests for troponin 
(www.accessdata.fda.gov, 2015). The majority of the tests for troponin are of moderate 
complexity. Many studies have been performed that show the time to diagnosis is faster 
when POC testing is used (Goodacre et al., 2011). Electrocardiogram testing and POC 
devices measuring cardiac troponin I levels have been used in a moving ambulance and 
showed good correlation to tests that were performed in the ED (Venturini et al., 2013).
Lee et al. (2013) recently introduced a centrifugally actuated POC testing system for cardiac 
troponin I. This microfluidic system performed a sandwich immunoassay with gold 
nanoparticles, and the fluid manipulation was controlled via centrifugation. It was shown to 
quantify physiological levels of cTnI in different clinical fluids (plasma and whole blood), 
and the coefficient of variation was less than 10% from 10 pg/mL to 25 ng/mL. It also 
showed excellent correlation to the system used in the clinical laboratory.
5.2. Acute heart failure: natriuretic peptide testing
Heart failure is the inability of the ventricles to either fill with or eject blood and needs to be 
treated as quickly as possible. In emergency medicine, patients experiencing heart failure 
typically present with shortness of breath (i.e., dyspnea). However, this symptom is 
associated with other causes such as asthma, pneumonia, and obstructive pulmonary disease. 
Therefore, treatment depends on diagnosing the underlying cause. This places an incredible 
burden on EDs (Peacock et al., 2010, Storrow et al., 2014).
One diagnostic biomarker that has shown potential to be effective in diagnosing heart failure 
is B-type natriuretic peptide (Cowie et al., 2003). B-type natriuretic peptide (BNP, originally 
termed brain natriuretic peptide) is synthesized from the myocytes in the ventricles and 
secreted in response to myocardial stretch. Atrial natriuretic peptide (ANP) is synthesized by 
the myocytes in the atria and C-type natriuretic peptide (CNP) is produced by the vascular 
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endothelial cells. These peptides effectively lower the extracellular fluid volume and blood 
pressure throughout circulation (O'Donoghue and Braunwald, 2010).
POC tests for BNP and the amino-terminal co-metabolite (NT-proBNP) have often been 
used to assist in the determination of underlying cause (Clerico et al., 2012, Mayo et al., 
2006). For emergency care patients, this test should be performed within one hour of blood 
collection (Carpenter et al., 2012). Because timely diagnosis and treatment of acute heart 
failure result in improved outcomes, this is a valuable target for POC applications. BNP 
POC testing may also find future use in risk stratification and guiding therapeutic decisions 
of acute coronary syndromes, like AMI (Sabatine et al., 2002). Other diagnostic tools to 
diagnose the etiology of dyspnea include electrocardiogram, chest x-ray, and 
cardiopulmonary ultrasound (Gallard et al., 2015, Pirozzi et al., 2014).
The majority of the commercially available tests for BNP are deemed to have moderate 
complexity. Currently, the only commercially available CLIA-waived test for BNP is the 
Alere Triage MeterPro (Figure 2). The Alere Triage system is a fluorescent POC system 
which comprises a portable reader (Triage Meter) and the assay cartridge for the given 
analyte(s) of interest. The system is based on a fluorescence immunoassay, so the portable 
meter is an optical system that excites the region of interest with a laser diode (670 nm) and 
measures the fluorescence emission (760 nm) with a silicon photodiode. Upon loading the 
sample, the test cartridge filters red blood cells and directs the sample through various zones 
via capillary action toward the capture spots that are being interrogated. One zone includes 
antibody-coated latex particles that recognize one epitope of the analyte of interest. These 
particles achieve a large Stokes shift by incorporating a pair of fluorescent dyes that undergo 
Fӧrster Resonance Energy Transfer (FRET) (Koshy and Buechler, 2013). The test can accept 
whole blood, plasma, or urine, and has an assay time of approximately 15 minutes. In 
addition to BNP, the Alere Triage system has quantitative tests for D-dimer, myoglobin, CK-
MB, and troponin I and qualitative tests for various drug screenings (www.alere.com, 2015).
5.3. Future directions
Future advances in POC diagnostics in the emergency room are first and foremost tied to an 
improved understanding of the biology. For many diseases, the biomarkers used in the 
diagnosis have continued to evolve (e.g., AMI). In other diseases, groups have yet to identify 
suitable sets of biomarkers that provide actionable diagnostic information. In addition, there 
is a growing awareness that the concentrations of the biomarkers are likely different among 
different patient groups, and guidelines for normal and abnormal levels need to be well 
established for gender, age, and race. As new biomarkers and panels of biomarkers are 
correlated with disease states for different groups, diagnostic tests will be developed to 
quantify those biomarkers in the appropriate setting. Because of the current, established 
workflow in a majority of the hospitals in the US, these diagnostic tests are typically first 
developed for use in the clinical laboratory. However, for emergency applications where 
immediate results could enable more efficient treatment, these diagnostic tests could be 
converted to a POC format.
Pressing applications that could significantly benefit from POC tests in the emergency room 
include diagnostics to distinguish ischemic stroke from hemorrhagic stroke and those that 
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distinguish severe cases of sepsis. In the case of stroke, the faster identification of an 
ischemic stroke could allow the tissue plasminogen activator to be delivered to degrade the 
culprit clot and restore blood flow. The time between the initial onset of the stroke to the 
initiation of thrombolysis is inversely related to the probability of disability-free recovery. 
Sepsis – a whole-body inflammatory response to an infection – can quickly progress to 
septic shock and needs to be treated early to improve chances for survival. Many emergency 
departments have protocols to diagnose and treat sepsis quickly. However, approximately 
25% of the cases that present with systemic inflammatory response syndrome actually have 
sepsis, leading to the over-administration of broad-spectrum antibiotics. The identification of 
biomarker panels that can improve the sensitivity and specificity for stroke and sepsis would 
immediately be useful in a POC format for the emergency room.
6. Operating room
The operating room is another location where POC diagnostic tests can significantly 
improve healthcare delivery. Surgeries are associated with a very high cost due to a number 
of factors, and many of these factors are a function of time (Fischer, 1999, Ismail et al., 
2015, Macario, 2010). Certain diagnostic tests have been shown to be useful in the 
perioperative setting to improve patient outcomes. Point-of-care testing has been shown to 
decrease the turnaround time of such tests, which can potentially improve patient care and 
decrease costs (Kost, 1995). There are a few good reviews for POC testing in the operating 
room (Rhee and Kahn, 2010, Salem et al., 1991). Here we briefly describe the use of 
diagnostic tests for coagulation monitoring and hemoglobin monitoring in the perioperative 
setting. Other commonly used POC tests in the operating room include blood gas analyzers 
(De Koninck et al., 2012, Poesen et al., 2013, Schlebusch et al., 2001) and glucose 
monitoring for patients with diabetes (Aldam et al., 2014, Rebel et al., 2012, Rice et al., 
2010).
6.1. Coagulation monitoring
Coagulation is a normal process of the body by which blood forms clots, and it is triggered 
by the rupturing of endothelium. Exposure of the blood to certain extravascular factors 
induces the clotting cascade to initiate clot formation (Davie et al., 1991). Natural 
anticoagulant mechanisms ensure that this clotting cascade is not induced under normal 
conditions, but there are many disorders associated with these mechanisms that increase the 
risk of clotting (Esmon, 1987). In response to these disorders, many people are placed on 
anticoagulant therapy, with drugs such as warfarin or heparin, to decrease their risk for an 
adverse clotting event (e.g., heart attack and stroke) (Hirsh, 1991, Hirsh et al., 1998, Hirsh et 
al., 2003). However, the dosage of the anticoagulant therapy needs to be personalized for 
each person to minimize the risk associated with clot formation and hemorrhaging. The 
personalized therapy is often determined with the use of coagulation monitoring. These tests 
are frequently performed using standard laboratory tests. Plasma is typically used, and it 
takes 30–60 minutes until results are available. For locations like the emergency or operating 
room, this turnaround time is not suitable (Faraoni et al., 2013). In response, various POC 
tests have been developed for coagulation monitoring, but no single technique provides 
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information for all aspects of the complex clotting process. There are many comprehensive 
reviews on the subject (Harris et al., 2013).
There are several techniques used in portable tests for coagulation monitoring, and most of 
them are versions of the traditional laboratory tests. This includes activated clotting time 
(Bittl, 2005), thrombelastography, rotational thromboelastometry (Mallett and Cox, 1992, 
Saner, 2014, Thölking et al., 2015), and platelet function (Agarwal et al., 2015, Petricevic et 
al., 2015). Many of the in vitro diagnostic tests attempt to extract information on certain 
pathways of the clotting cascade, primarily extrinsic and intrinsic pathways. Prothrombin 
time (PT) and activated partial thromboplastin time (aPTT) are the most frequently used 
tests to determine functionality of the blood coagulation system. Currently, the only CLIA-
waived devices for coagulation monitoring measure the PT. These PT values are commonly 
converted into an internationally normalized ratio (INR) to enable the comparison of PT 
values between analytical methods. Devices that are currently waived include the 
CoaguChek XS Plus from Roche (Figure 2), Coag-sense, and Hemosense INR. Some of 
these are available for use at the home, and studies have shown that their use increases the 
time that the patient's INR is in the targeted, therapeutic range for the given anticoagulant 
(Okuyama et al., 2014).
Many groups have compared the use of POC tests with laboratory analyzers directly 
(Herbstreit et al., 2010). Peña et al. (2012) recently compared the PT/INR results with a 
POC device (i-STAT) and a central laboratory coagulation analyzer (Tcoag MDA II 
analyzer), and they showed that it compares well when performed by phlebotomists or 
nurses. Bardakci et al. (2013) compared the INR value of patients with CoaguChek XS 
handheld coagulation analyzer from Roche Diagnostics with the automatic analyzer Sysmex 
CA-7000 from Siemens for the purposes of open–heart valve surgery. These patients had 
been administered vitamin K antagonists with low molecular weight heparin. Patients with 
diabetes mellitus were excluded from the study, because previous studies showed some 
deviations of POC INR values compared to standard methods in diabetic patients. 
Preoperative and postoperative measurements on the POC test correlated strongly with the 
conventional methods of laboratory testing (Bardakci et al., 2013).
Additional research efforts are designing improved devices for use at the point-of-care. 
Dudek et al. (2010) developed a single-use microfluidic device to measure fibrinogen in 
human plasma, requiring only 15 μL of plasma. Micropillars in the device induced capillary 
pressure which induced flow through dried thrombin reagent, converting soluble fibrinogen 
to insoluble fibrin. The insoluble fibrin induces a clot, causing the flow of the plasma within 
the microfluidic device to stop. Within five minutes, the fibrinogen concentration can be 
determined by measuring the distance traveled (Dudek et al., 2010). Li et al. (2014) have 
recently developed a simple paper-based lateral flow device for blood coagulation screening. 
Using the capillary pressure of the paper to wick the whole blood, the changes of viscosity 
due to coagulation could be identified by tracking the rate that the fluid imbibes (Li et al., 
2014). Cakmak et al. (2015) have recently developed a multiplexed MEMS-based sensing 
cartridge that can test for both PT and aPTT in plasma. Microfluidic channels were 
functionalized with dried reagent to add factors to the plasma as the fluid passively flows 
following loading. The time-dependent viscosity affects the oscillation of a microcantilever 
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that is measured remotely with a laser. By having both measurements of a single sample, 
both pathways of the clotting cascade (intrinsic and extrinsic) are described (Cakmak et al., 
2015). Other groups are developing fluorogenic sensors that become fluorescent upon 
exposure to heparin to quantify the heparin concentration (Cao et al., 2014, Cheng et al., 
2013, Gu et al., 2012).
6.2. Hemoglobin monitoring
Hemoglobin monitoring is often used alongside coagulation monitoring to determine the 
extent of blood loss during surgery. In the case of extreme blood loss, the first-line therapy is 
the transfusion of red blood cells to mitigate the risk of hypoxia associated with the lost 
blood. However, transfusions are associated with severe side effects (Hogervorst et al., 
2014), and unnecessary transfusions have been shown to increase patient morbidity (Giraud 
et al., 2013).
Evidence-based practice has shown that there is not a ‘one-value for all’ for the hemoglobin 
measurement where the treatment is considered beneficial to the patient and demographics, 
comorbidities, and physiologic variables need to be considered. However, as a general rule, 
transfusion has been shown to be useful at a hemoglobin concentration less than 7 g/dL, and 
it is not needed at concentrations greater than 10 g/dL in adults. Normal values range from 
12 to 17 g/dL. The American Association of Blood Banks (AABB) guidelines recommend 
that perioperative transfusion at a hemoglobin concentration less than 8 g/dL (Carabini et al., 
2015). Groups have shown that the monitoring of hemoglobin reduces the frequency of 
blood transfusions with no negative impact on patient safety (O'Reilly, 2012).
Because hemoglobin values can change dramatically in the OR, the shorter turnaround times 
of POC tests for hemoglobin have been found to be useful. These POC diagnostic tests are 
either minimally invasive (require small volumes of blood) or are non-invasive. There are 
many CLIA-waived tests for hemoglobin. The HemoCue Hb201+ is a CLIA-waived, 
minimally-invasive system that requires 10 μL of sample to generate a reading in less than 
one minute (Figure 2). It can use capillary blood from a finger-stick and performs a modified 
azide methemoglobin reaction with reagents that are stored on chip to elicit a hemoglobin 
dependent color change (Skelton et al., 2013). Non-invasive systems for hemoglobin 
monitoring include systems that use multi-wavelength co-oximetry (Radical-7 and Pronto-7 
from Masimo) and occlusion spectroscopy (NBM-200 from Orsense). Both of these types of 
systems have been shown to perform well in the intensive care and emergency departments 
as well as operating rooms (Kim et al., 2014a).
6.3. Ongoing research
In addition to the development of POC diagnostics for cardiac applications, another area of 
research is the development of POC diagnostic tests to quantify hormones during the 
surgical removal of the respective endocrine glands. Here, we detail the history of using 
intraoperative parathyroid hormone monitoring to guide surgery and highlight ongoing 
developments toward a POC diagnostic test. Similar POC diagnostic tests could also apply 
to other hormones of the endocrine system like insulin, ACTH, growth hormone, and 
gastrin.
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Parathyroid hormone (PTH) is an 84 amino acid peptide (9.4 kDa) that is involved in 
calcium regulation (Potts, 2005). It is secreted by the parathyroid glands located in the neck 
and its receptor is located in several tissues including the kidney and bone. PTH stimulates 
these tissues to increase calcium levels in the circulation (Fraser et al., 2013). These glands 
are hyperfunctioning in disorders such as primary hyperparathyroidism, and the only 
definitive cure is achieved by a parathyroidectomy (Callender and Udelsman, 2014, Khan, 
2013, Yu et al., 2011). Because the circulating half-life of PTH is short (<5 minutes), the 
circulating concentrations of PTH are expected to dramatically decrease upon removal of all 
affected glands (Bieglmayer et al., 2006). Intraoperative parathyroid hormone monitoring 
has demonstrated clinical utility in guiding surgeons to whether all culprit parathyroid 
glands have been removed (Johnson et al., 2001). While there is work being done to 
determine whether this monitoring is needed for all, it has been shown to decrease the rates 
of re-hospitalization for many patients (Hwang et al., 2010, Stalberg et al., 2006). 
Intraoperative monitoring has been found useful during the removal of other endocrine 
glands as well (Sokoll et al., 2004).
There are various criteria that have been used to predict successful cure for IOPTH 
monitoring, but the Miami criterion is the most widely known (Carneiro et al., 2003). This 
states that successful cure can be predicted if there is a 50% drop in baseline PTH after 10 
minutes of gland removal (Irvin Iii et al., 1994). Many different rapid IOPTH tests were 
developed to have the required sensitivity and assay time to allow for practical use in 
surgical management (Carneiro and Irvin, 2002, Goodman, 2005, Skugor et al., 2010, Vieira 
et al., 2006). The majority of these assays use a sandwich immunoassay with capture and 
detection antibodies that recognize unique epitopes of PTH. Many of these assays have been 
compared with one another, and they have shown some key differences (Cole et al., 2007, 
La'ulu and Roberts, 2010, Santini et al., 2004). The differences in reported values between 
assays can potentially be attributed to the different recognition elements used in the 
diagnostic tests. These have varying cross-reactivities to the heterogeneous mixture of 
metabolized fragments in circulation (Gao and D'Amour, 2005, Silverman and Yalow, 1973). 
This is further complicated because the longer fragments have a significantly longer 
circulating half-life than the 1-84 PTH (Vieira et al., 2009).
Assay incubation times range from 10–30 minutes, and the majority of institutions send 
samples to the core clinical lab for analysis (Hortin and Carter, 2002). The transport times 
can lead to lengthy turnaround times – up to an hour in length. Other institutions have used 
satellite testing close to the operating room to improve turnaround time, but these tests 
require an instrument and a laboratory technician to comply with CLIA as all tests to date 
are either moderate or high-complexity tests (Wians et al., 2000). Normal PTH values range 
from 10–70 pg/mL (1-7 pM) (Kratz et al., 2004). In primary hyperparathyroidism, baseline 
PTH values can be higher than 1500 pg/mL. Groups have also explored more complicated 
mathematical algorithms and models to enable more accurate predictions of cure 
(Bieglmayer et al., 2002, Richards et al., 2011, Udelsman et al., 2014). Other groups have 
used the PTH assay as a replacement for frozen sectioning (Conrad et al., 2006, Guarda, 
2004).
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In an attempt to develop improved PTH tests for the point-of-care in the operating theater, 
there have been some recent efforts to develop new diagnostic devices (Dittmer et al., 2008, 
Özcan and Sezgintürk, 2015, Sayikli ŞimŞek et al., 2015). Perhaps most notably, Philips has 
developed an intraoperative PTH assay based on their handheld magnotech technology 
(Bruls et al., 2009, Jarrige et al., 2011). This test uses a disposable, self-contained cartridge 
that contains all assay reagents -including magnetic nanoparticles functionalized with a 
monoclonal antibody that recognizes the N-terminus (1-34) of PTH - in dry form. Magnetic 
forces transport particles to the surface, increasing the concentration of analyte near the 
recognition elements (antibodies that recognize C-terminus (39-84) of PTH) at the surface. 
These forces are then used to remove unbound particles. The bound nanoparticles are 
transduced with the principle of frustrated total internal reflection. The assay requires <25 
μL of sample (EDTA-treated plasma) and takes eight minutes. Philips has also developed a 
cardiac troponin test using this technology (Dittmer et al., 2010).
6.4. Future directions
A primary role of all POC diagnostic tests is to expedite the process of obtaining test results, 
but the operating room has a unique set of requirements for such a test. Moving POC 
diagnostics into the operating room reduces the sample-to-answer time by eliminating 
sample transport to a central laboratory, which can reduce the time that a patient is open 
and/or under anesthesia; any reduction in the actual time required to perform the diagnostic 
test is additionally advantageous. Inside an operating room there is limited space with many 
workers, and each of these workers has a specific role with a list of responsibilities. New 
POC tests would most likely need to be CLIA-waived to be used in the operating room 
without additional personnel, so it must be simple and have a low risk for error.
Because of these characteristics, any biomarker information measured with a POC 
diagnostic during surgery needs to provide information essential to a successful surgery and 
the patient's recovery thereafter. The tests should offer immediate feedback relevant to the 
treatment while the surgery is in process. Therefore, POC diagnostics should either be used 
to track the overall health of the patient or to monitor the progress of the surgery. Because of 
the transient nature of surgery, tracking the rates of change in biomarker concentrations 
might offer operating room personnel key insights on the how the body is responding to 
surgery. Sequential measurements could be performed with a POC diagnostic and the 
portable reader could use predefined algorithms to anticipate problems or validate success. 
In addition, adding test results to the permanent medical record may provide information 
important for post-operative care.
7. Conclusions
Most commercially available portable point-of-use tests for specialty applications rely on 
lateral flow tests, real-time PCR, electrochemical monitors, or simple microfluidic cassettes 
inserted into a reader. The rapid progress in miniaturization of optical devices offers optical 
readout systems comparable in cost and size to electrochemical glucose-type readers; 
making readers using cell phone components and using cell phones as readers are 
approaches already in the research and development phase. For making even smaller and 
Cummins et al. Page 24
Biotechnol Adv. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
disposable diagnostic devices, organic light emitting diodes and photodiodes can be 
incorporated into inexpensive, credit-card sized tests in the same substrate as the electronics 
and microfluidics. While still a step behind the optics and electronics, fluidic components 
are being tested that will facilitate more complex sample processing and signal amplification 
without the need for relatively large pumps and valves. Increased automation, improved 
ability to distinguish signal from background, and user sophistication are three factors that 
open the doors to new tests for generating information not available in the past outside of a 
laboratory.
The drivers for the development of new tests vary with the particular application. Veterinary 
POC diagnostics will continue to expand to diseases that are currently unmonitored or only 
diagnosed in central laboratories. Infectious diseases are high value targets, especially if they 
affect food or companion animals or if the disease is transmissible from animals to people. 
New optoelectronic materials, robust recognition molecules, integrated components, and 
automation are all critical features that will open new opportunities for veterinary 
diagnostics. In the last few years, the availability of portable infrared spectrometers has 
begun to foster the exploration of spectroscopy as a rapid method for measuring changes in 
tissues, milk and clinical fluids (e.g. Santos et al., 2013; Samara et al., 2014); this is only the 
tip of the iceberg in what may be feasible using handheld imaging and spectroscopy tools.
The renewed interest in long-term space flight demands the development of next-generation 
POC modular diagnostics that are reusable and capable of diagnosing a wide variety of 
medical conditions. It also demands further research into the behavior of fluids in 
microgravity and a re-thinking of how to manipulate fluids in such an environment. For 
example, recent advances in paper fluidics-based diagnostics provides a possible approach 
for performing assays in microgravity environment (Martinez et al., 2010). In addition, more 
research is needed on the long-term effects of space on human physiology. As these 
fundamental studies improve our understanding of the effect of microgravity on human 
health, new POC diagnostics can be developed to monitor the vital physiological parameters 
to maintain optimal health for astronauts.
Even though doping testing continues to rely on traditional lab-scale technology such as 
mass spectrometry, a portable POC diagnostic could be valuable in testing athletes during a 
competition. Continued advances in miniaturization will produce portable mass 
spectrometry systems that could meet this need. Indeed, portable mass spectrometers are 
already commercially available for military and first-responder applications (e.g., the M908 
from 908 Devices, Boston, MA) and adapting these devices to non-emergency applications 
would be straightforward. Simpler tests, such as amplified immunoassays, have the potential 
to address the need for a POC test for traumatic brain injury; however, the clinical 
information is first required to determine which biomarkers are most appropriate to measure.
Lastly, emergency and operating room medicine will continue to evolve. To date the 
development of these POC tests has been rather haphazard—a clinician, scientist or engineer 
realizes a particular need and formulates an approach to address that need. A comprehensive 
analysis of what POC diagnostics would most expedite patient care in the ED could focus 
corporate attention on adapting existing clinical laboratory tests to simple, single-use 
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formats to solve problems that are high impact, even if not high profile. Tests in the 
operating room currently focus on monitoring the impact of anesthesia and general physical 
parameters. As pharmacoengineering produces new approaches for drug delivery in concert 
with surgical procedures, biochemical monitors during surgery must become more 
sophisticated. Keeping the devices used to perform such assays as simple as possible is 
essential to their use.
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Figure 1. 
Diagram that highlights the differences in workflow between using traditional laboratory 
testing and point-of-care testing. From (Larsson et al., 2014).
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Figure 2. 
Most portable diagnostic tests can be categorized as a wearable test (top-left), a cartridge-
based test that does not need a reader (bottom-left), a cartridge-based test that needs a 
handheld reader (top-right), or a cartridge-based test that needs a tabletop reader (bottom-
right). These subcategories range from being the most portable to the least portable. In the 
top-left, an absorbent pad wicks sweat to pH sensitive ionogels which change color in 
response different pH levels. From (Curto, Fay, 2012). In the top-right, examples are shown 
of the Coaguchek XS System (www.coaguchek.com, 2016), the HemoCue Hb 201+ System 
(www.hemocue.us, 2016), and the i-STAT portable blood chemistry analyzer 
(www.abbottpointofcare.com, 2015). The lower-left shows a SNAP test by IDEXX (top) and 
an Abaxis lateral flow assay for the detection of heartworm disease (bottom). From 
(O'Connor, Lawrence, 2013) and (www.abaxis.com, 2015e), respectively. The lower-right 
image shows the Alere Triage system (www.alere.com, 2015).
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Table 1
Criteria for the categorization of CLIA lab test. After (Collopy, Kivlehan, 2014).
Criteria Score of 1 Score of 3
Knowledge Minimal scientific and technical knowledge 
required; may be taught on the job
Specialized scientific knowledge required to 
perform preanalytic, analytic or postanalytic 
testing
Training and experience Minimal training or limited experience required to 
perform test
Specialized training is essential or substantial 
experience necessary for test performance
Reagents and materials Reagents and materials are stable and reliable; they 
are prepackaged or premeasured with no special 
handling required
Reagents and materials may be labile and require 
special handling. Preparation may include manual 
steps such as volumetric measurements
Characteristics of operational 
steps
Operational steps are either automatically executed 
or easily controlled
Steps require close monitoring or control; may 
require special preparation, precise temperature 
control or procedural steps
Calibration, quality control and 
proficiency testing
Calibration and QC materials are stable and readily 
available
Calibration, and proficiency materials may be 
labile
Test system troubleshooting Troubleshooting is automatic Troubleshooting requires
and equipment maintenance or self-correcting or requires minimal judgment. 
Maintenance is seldom required and can be easily 
performed
decision making and direct intervention to solve 
most problems. Maintenance requires special 
knowledge and skills
Interpretation and judgment Test processes require minimal judgment or 
interpretation
Testing processes require extensive judgment, 
resolution of problems requires extensive 
interpretation
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Table 2
Identified conditions that shall be treatable in space and that require fluid analysis. From the Exploration 
Medical Capability (ExMC) Evidence Report. After (humanresearchwiki.jsc.nasa.gov, 2015c).
Medical Conditions
Burns Pharyngitis
Cellulitis Prostatitis
De Novo Cardiac Arrhythmia Radiation Sickness
De Novo Hypertension Respiratory Infection
Decompression Sickness Seizure
Diarrhea Sepsis
Headache Space Motion Sickness (Space Adaptation)
Intra-abdominal Infection Surgical Treatment
Nausea/Vomiting Toxic Exposure
Neck Injury Urinary Incontinence (Space Adapation)
Nephrolithiasis Urinary Retention (Space Adapatation)
Nosebleed (Space Adaptation) Urinary Tract Infection
Osteoporosis
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